Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11504808 | 0.86 | NOX1 (0.77) | MAPTALDH1A1NOX1LMNASMN1; SMN2 | |
| SCHEMBL14602472 | 0.81 | ALDH1A1 (0.71) | GAAMAPTALDH1A1KDM4ELMNA | |
| SCHEMBL6097058 | 0.81 | SMN1; SMN2 (0.69) | GAAMAPTALDH1A1KDM4ELMNA | |
| SCHEMBL11855568 | 0.80 | GAA (0.65) | GAAMAPTALDH1A1KDM4ENOX1 | |
| SCHEMBL8423522 | 0.80 | GAA (0.65) | GAAMAPTALDH1A1KDM4ENOX1 | |
| SCHEMBL2243625 | 0.80 | GAA (0.70) | GAAMAPTALDH1A1KDM4ENOX1 | |
| SCHEMBL11606488 | 0.80 | LMNA (0.68) | GAAMAPTALDH1A1KDM4ENOX1 | |
| SCHEMBL11140033 | 0.79 | GAA (0.68) | GAAMAPTALDH1A1KDM4ENOX1 | |
| SCHEMBL16566591 | 0.79 | ALDH1A1 (0.69) | GAAMAPTALDH1A1 | |
| SCHEMBL9053644 | 0.79 | SMN1; SMN2 (0.78) | GAAMAPTALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | FFAR4, FFAR1, MSR1 | GAA 4801/4885MAPT 4387/4885ALDH1A1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.